- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Stephen Silberstein Discusses Erenumab Use for Menstrual Migraine
If you only experience migraine with your period for a few days, it would be difficult to recommend taking a drug all the time, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.
If you only experience migraine with your period for a few days, it would be difficult to recommend taking a drug all the time, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.
Transcript:
The American Journal of Managed Care®(AJMC®): Results from STRIVE found erenumab is a safe and effective option for treating menstrual migraine. Do you think erenumab will be indicated for this condition in the near future?
Dr. Silberstein: There are 2 types of menstrual migraine. There's pure menstrual migraine when women only have migraine with their period and there's menstrual migraine that occurs at any other time. So if you only have migraine with your period for a couple days, I think it would be difficult to recommend taking a drug all the time just for a headache that only occurs 3 days a month. If you have menstrual migraine plus other migraine, and it's intractable, obviously, they should get treatment. There are other treatment options, short-term treatment options, for hormonal treatment for women with pure menstrual migraine.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
